Российский кардиологический журнал (Sep 2015)

PRACTICAL CONCERNS OF ANTICOAGULATION IN NONVALVULAR ATRIAL FIBRILLATION: A UNIVERSITY CLINICS REGISTRY

  • A. A. Sokolova,
  • A. V. Zhilenko,
  • I. L. Tsarev,
  • D. A. Napalkov,
  • V. A. Sulimov

DOI
https://doi.org/10.15829/1560-4071-2015-9-32-37
Journal volume & issue
Vol. 0, no. 9
pp. 32 – 37

Abstract

Read online

Aim. To evaluate the possibility to increase the effectiveness and safety of anticoagulation therapy in nonvalvular atrial fibrillation (AF) under the circumstances of an office for anticoagulation control located at the University Clinics.Material and methods. Observational prospective study (registry), included 325 patients with nonvalvular AF, taking various anticoagulation drugs for the prevention of thromboembolic complications (TEC). Mean duration of follow-up is 24±12 months.Results. At the current moment about 95% of patients continue taking anticoagulants and follow-up in the office of anticoagulation control. Totally there were 37 bleedings marked, of those 19 minor and 18 major. By the general quantity of bleeding cases there is no significance in the difference between warfarin and “novel” anticoagulants (NOAC) (p>0,05). Major bleedings significantly more common in warfarin group than in NOAC (p<0,05), and absolute number of minor is lower in warfarin group (p<0,05). By the total number of bleedings anticoagulants ranged as following: dabigatran (in 5,13% of patients), warfarin with time in target INR more than 40% (10,34%), rivaroxaban (14,3%), apixaban (26,9%). Higher rate in apixaban can be explained by older mean age of the patients taking it (p<0,05), that is itself a risk factor for hemorrhagic complications. It should be marked that by the rate of major bleedings warfarin was significantly worse, than any NOAC. During follow-up time thromboembolic complications were found just in 3% (0,9% of all taking anticoagulants).Conclusion. Anticoagulation control under the conditions of specialized office is effective and safe for the patients with nonvalvular AF. On vitamin K antagonists (even in good INR control) there are significantly more common major (potentially life-threatening) bleedings, though in NOAC treatment there are more minor bleedings that require only short interruption of drug intake.

Keywords